Business Description
Abionyx Pharma
ISIN : FR0012616852
Share Class Description:
XPAR:ABNX: Ordinary SharesCompare
Compare
Traded in other countries / regions
ABNX.France609.Germany0RAG.UK IPO Date
2015-03-25Description
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.67 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | -1 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.35 | |||||
| Beneish M-Score | -2.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -11.3 | |||||
| 3-Year EPS without NRI Growth Rate | -13.8 | |||||
| 3-Year FCF Growth Rate | -57.5 | |||||
| 3-Year Book Growth Rate | -3.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -13.68 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 38.53 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.1 | |||||
| 9-Day RSI | 62.1 | |||||
| 14-Day RSI | 59.92 | |||||
| 3-1 Month Momentum % | -0.16 | |||||
| 6-1 Month Momentum % | -3.12 | |||||
| 12-1 Month Momentum % | 11.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.28 | |||||
| Quick Ratio | 2.22 | |||||
| Cash Ratio | 1.6 | |||||
| Days Inventory | 18.01 | |||||
| Days Sales Outstanding | 51.21 | |||||
| Days Payable | 139.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | -14.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 19.19 | |||||
| Operating Margin % | -64.11 | |||||
| Net Margin % | -69.15 | |||||
| FCF Margin % | -64.23 | |||||
| ROE % | -45.45 | |||||
| ROA % | -22.83 | |||||
| ROIC % | -29.35 | |||||
| 3-Year ROIIC % | -3.24 | |||||
| ROC (Joel Greenblatt) % | -147.45 | |||||
| ROCE % | -32.06 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.91 | |||||
| PB Ratio | 4.52 | |||||
| Price-to-Tangible-Book | 11.07 | |||||
| EV-to-EBIT | -12.87 | |||||
| EV-to-EBITDA | -13.48 | |||||
| EV-to-Revenue | 8.83 | |||||
| EV-to-FCF | -13.75 | |||||
| Price-to-Net-Current-Asset-Value | 26.56 | |||||
| Earnings Yield (Greenblatt) % | -7.77 | |||||
| FCF Yield % | -6.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abionyx Pharma Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4.856 | ||
| EPS (TTM) (€) | -0.1 | ||
| Beta | 1.12 | ||
| 3-Year Sharpe Ratio | -0.31 | ||
| 3-Year Sortino Ratio | -0.41 | ||
| Volatility % | 29.58 | ||
| 14-Day RSI | 59.92 | ||
| 14-Day ATR (€) | 0.045775 | ||
| 20-Day SMA (€) | 1.2568 | ||
| 12-1 Month Momentum % | 11.07 | ||
| 52-Week Range (€) | 0.91 - 1.5 | ||
| Shares Outstanding (Mil) | 34.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abionyx Pharma Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abionyx Pharma Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abionyx Pharma Frequently Asked Questions
What is Abionyx Pharma(XPAR:ABNX)'s stock price today?
The current price of XPAR:ABNX is €1.33. The 52 week high of XPAR:ABNX is €1.50 and 52 week low is €0.91.
When is next earnings date of Abionyx Pharma(XPAR:ABNX)?
The next earnings date of Abionyx Pharma(XPAR:ABNX) is .
Does Abionyx Pharma(XPAR:ABNX) pay dividends? If so, how much?
Abionyx Pharma(XPAR:ABNX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers